Rhythm Biosciences Limited (ASX:RHY)
Australia · Delayed Price · Currency is AUD 0.1750
-0.0150 (-7.89%)
At close: Feb 4, 2026
Rhythm Biosciences Revenue
In the fiscal year ending June 30, 2025, Rhythm Biosciences had annual revenue of 3.19M AUD with 88.85% growth. Rhythm Biosciences had revenue of 25.63K in the half year ending June 30, 2025, a decrease of -93.16%.
Revenue
3.19M
Revenue Growth
+88.85%
P/S Ratio
17.93
Revenue / Employee
n/a
Employees
n/a
Market Cap
57.24M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 3.19M | 1.50M | 88.85% |
| Jun 30, 2024 | 1.69M | -1.41M | -45.41% |
| Jun 30, 2023 | 3.10M | 668.44K | 27.54% |
| Jun 30, 2022 | 2.43M | 1.32M | 118.98% |
| Jun 30, 2021 | 1.11M | 1.01M | 1,008.51% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Healius | 1.34B |
| Australian Clinical Labs | 741.27M |
| Integral Diagnostics | 627.22M |
| Monash IVF Group | 271.92M |
| Genetic Signatures | 19.75M |
| Microba Life Sciences | 15.67M |
| Cryosite | 14.12M |
| Genetic Technologies | 9.17M |